About Hospido
Hospido is a Healthcare company based in Gurugram (India) founded in 2020. It provides an online teleconsultation platform specialized in cancer treatment. It operates on a B2C model. The company has 1 employees. Its Indian entity Hospido Private Limited reported revenue of ₹72.34 Cr. Its focus areas include Healthcare and Medical, Telemedicine, Consultation Services and Cancer Care. Its competitors include CancerMitr and OncoWellbility.
Company details
Hospido, established in 2020, excels in healthcare and medical, telemedicine, consultation services, and cancer care. Provides an online teleconsultation platform specialized in cancer treatment. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Gurugram, India
- Employees 1
- SectorsHealthcare
- Website hospido.in
- Social X Facebook
- Legal Name Hospido Private Limited
- Date of Incorporation 06 Jun, 2020
- Jurisdiction New Delhi, Delhi, India
- Annual Revenue₹72.34 Cr
FY 2024 · +704% YoY
- Net Profit₹18.17 Cr
FY 2024 · 25% margin
- EBITDA₹24.39 Cr
FY 2024 · 34% margin
- Employee Count1
Associated legal entities of Hospido
Hospido operates through Hospido Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Hospido Private Limited CIN U85300DL2020PTC364444 | Active | 06 Jun 2020 | New Delhi, Delhi | ₹72.3 Cr | 20 | 2 | View details |
Board of directors of Hospido Private Limited (Hospido)
Hospido Private Limited is the primary company behind Hospido. The board of Hospido Private Limited currently have 2 directors; the longest-serving is Karan Chopra, appointed in 2020. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Karan Chopra DIN 08755648 | Director | 06 Jun 2020 | 6 yrs 4 mo | Hospido Private Limited |
| Sundeep Kalsi DIN 01493597 | Director | 19 Apr 2024 | 2 yrs 5 mo | Hospido Private Limited |
Financials of Hospido
Figures of Hospido Private Limited, the primary company behind Hospido, for FY 2024. Revenue was ₹72.34 Cr (+704% year on year). Net profit was ₹18.17 Cr (25% margin). EBITDA was ₹24.39 Cr (34% margin). Revenue has grown at a compounded annual rate of +1156% over three years.
- ₹72.34 CrRevenue · FY 2024 · +704% YoY
- ₹18.17 CrNet profit · 25% margin
- ₹24.39 CrEBITDA · 34% margin
- ₹50 LakhPaid-up capital
- 20Employees (provident fund records)
- +1156%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Hospido Private Limited are on its company page.
Detailed financial statements for Hospido
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Hospido
Hospido has 2 listed competitors in our database. They include CancerMitr and OncoWellbility, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cancermitr.com | 2021 | Mumbai, India | – | 7 | Digital teleconsultations are facilitated for cancer patients and doctors. | |
| oncowellbility.com | 2020 | Bengaluru, India | – | – | Provides a digital healthcare platform specialized for cancer patients. |
Detailed competitors of Hospido
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
10 companies that operate in the same segment as Hospido (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hospido
Complete news archive for Hospido
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hospido
Hospido was founded in 2020.
Hospido is headquartered in Gurugram, India. It is registered at Gurugram, Haryana, India.
Hospido has 1 employees.
The primary company behind Hospido, Hospido Private Limited, reported revenue of ₹72.34 Cr for FY 2024, up 704% year on year.
Hospido, established in 2020, excels in healthcare and medical, telemedicine, consultation services, and cancer care. Provides an online teleconsultation platform specialized in cancer treatment. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide. It continues to evolve, meeting industry challenges with strategic approaches.
Hospido's top competitors include CancerMitr and OncoWellbility.
Hospido operates through Hospido Private Limited.
The legal entities of Hospido currently have 2 directors, including Karan Chopra, Sundeep Kalsi.